The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patients.
- Published in:
- Immunological Reviews, 2023, v. 318, n. 1, p. 4, doi. 10.1111/imr.13270
- By:
- Publication type:
- Article
Works matching IS 01052896 AND DT 2023 AND VI 318 AND IP 1
Results: 15
1
2
Effects of immune‐related adverse events (irAEs) and their treatment on antitumor immune responses.
- Published in:
- Immunological Reviews, 2023, v. 318, n. 1, p. 167, doi. 10.1111/imr.13262
- By:
- Publication type:
- Article
3
Autoimmunity in immune checkpoint inhibitor‐induced immune‐related adverse events: A focus on autoimmune skin toxicity and pneumonitis.
- Published in:
- Immunological Reviews, 2023, v. 318, n. 1, p. 37, doi. 10.1111/imr.13258
- By:
- Publication type:
- Article
4
Cutaneous immune‐related adverse events from immune checkpoint inhibitor therapy: Moving beyond "maculopapular rash".
- Published in:
- Immunological Reviews, 2023, v. 318, n. 1, p. 22, doi. 10.1111/imr.13257
- By:
- Publication type:
- Article
5
Germline mechanisms of immunotherapy toxicities in the era of genome‐wide association studies.
- Published in:
- Immunological Reviews, 2023, v. 318, n. 1, p. 138, doi. 10.1111/imr.13253
- By:
- Publication type:
- Article
6
Stocking the toolbox—Using preclinical models to understand the development and treatment of immune checkpoint inhibitor‐induced immune‐related adverse events.
- Published in:
- Immunological Reviews, 2023, v. 318, n. 1, p. 110, doi. 10.1111/imr.13250
- By:
- Publication type:
- Article
7
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities.
- Published in:
- Immunological Reviews, 2023, v. 318, n. 1, p. 157, doi. 10.1111/imr.13249
- By:
- Publication type:
- Article
8
CD4 T cells and toxicity from immune checkpoint blockade.
- Published in:
- Immunological Reviews, 2023, v. 318, n. 1, p. 96, doi. 10.1111/imr.13248
- By:
- Publication type:
- Article
9
Immune‐related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity.
- Published in:
- Immunological Reviews, 2023, v. 318, n. 1, p. 81, doi. 10.1111/imr.13247
- By:
- Publication type:
- Article
10
Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor‐induced kidney disease.
- Published in:
- Immunological Reviews, 2023, v. 318, n. 1, p. 61, doi. 10.1111/imr.13243
- By:
- Publication type:
- Article
11
Rheumatic complications of checkpoint inhibitors: Lessons from autoimmunity.
- Published in:
- Immunological Reviews, 2023, v. 318, n. 1, p. 51, doi. 10.1111/imr.13242
- By:
- Publication type:
- Article
12
Mediators and mechanisms of immune checkpoint inhibitor‐associated myocarditis: Insights from mouse and human.
- Published in:
- Immunological Reviews, 2023, v. 318, n. 1, p. 70, doi. 10.1111/imr.13240
- By:
- Publication type:
- Article
13
Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions.
- Published in:
- Immunological Reviews, 2023, v. 318, n. 1, p. 11, doi. 10.1111/imr.13239
- By:
- Publication type:
- Article
14
Role of B cells in immune‐related adverse events following checkpoint blockade.
- Published in:
- Immunological Reviews, 2023, v. 318, n. 1, p. 89, doi. 10.1111/imr.13238
- By:
- Publication type:
- Article
15
Issue Information.
- Published in:
- Immunological Reviews, 2023, v. 318, n. 1, p. 1, doi. 10.1111/imr.13098
- Publication type:
- Article